Țară: Statele Unite ale Americii
Limbă: engleză
Sursă: NLM (National Library of Medicine)
RASAGILINE MESYLATE (UNII: LH8C2JI290) (RASAGILINE - UNII:003N66TS6T)
Teva Pharmaceuticals USA, Inc.
RASAGILINE MESYLATE
RASAGILINE 0.5 mg
ORAL
PRESCRIPTION DRUG
Rasagiline tablets are indicated for the treatment of Parkinson’s disease (PD). Rasagiline is contraindicated for use with meperidine, tramadol, methadone, propoxyphene, and MAO inhibitors (MAOIs), including other selective MAO-B inhibitors, because of risk of serotonin syndrome [see Warnings and Precautions (5.2)] . At least 14 days should elapse between discontinuation of rasagiline and initiation of treatment with these medications. Rasagiline is contraindicated for use with St. John’s wort and with cyclobenzaprine. Rasagiline is contraindicated for use with dextromethorphan because of risk of episode of psychosis or bizarre behavior. Risk Summary There are no adequate data on the developmental risks associated with the use of rasagiline in pregnant women. In animal studies, oral administration of rasagiline to rats during gestation and lactation resulted in decreased survival and reduced body weight in the offspring at doses similar to those used clinically. When administered to pregnant animals in combin
Rasagiline 0.5 mg Tablets: White to off-white, round, flat, beveled tablets, debossed with “GIL 0.5” on one side and plain on the other side. Supplied as bottles of 30 tablets (NDC 0093-3060-56). Rasagiline 1 mg Tablets: White to off-white, round, flat, beveled tablets, debossed with “GIL 1” on one side and plain on the other side. Supplied as bottles of 30 tablets (NDC 0093-3061-56). Storage: Store at 25°C (77°F) with excursions permitted to 15°-30°C (59°-86°F).
New Drug Application Authorized Generic
RASAGILINE- RASAGILINE TABLET TEVA PHARMACEUTICALS USA, INC. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE RASAGILINE SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR RASAGILINE. RASAGILINE TABLETS FOR ORAL USE INITIAL U.S. APPROVAL: 2006 INDICATIONS AND USAGE Rasagiline, a monoamine oxidase (MAO)-B inhibitor (MAOI), is indicated for the treatment of Parkinson’s disease (1) DOSAGE AND ADMINISTRATION Monotherapy: rasagiline 1 mg once daily (2.1) As adjunct without levodopa: rasagiline 1 mg once daily (2.1) As adjunct to levodopa: rasagiline 0.5 mg once daily. Increase dose to 1 mg daily as needed for sufficient clinical response (2.1) Patients taking ciprofloxacin or other CYP1A2 inhibitors: rasagiline 0.5 mg once daily (2.2, 5.4) Patients with mild hepatic impairment: rasagiline 0.5 mg once daily. Rasagiline should not be used in patients with moderate or severe hepatic impairment (2.3, 5.5) DOSAGE FORMS AND STRENGTHS Rasagiline 0.5 mg tablets (3) Rasagiline 1 mg tablets (3) CONTRAINDICATIONS Concomitant use of meperidine, tramadol, methadone, propoxyphene dextromethorphan, St. John’s wort, cyclobenzaprine, or another (selective or non-selective) MAO inhibitor (4) WARNINGS AND PRECAUTIONS May cause hypertension (including severe hypertensive syndromes) at recommended doses (5.1) May cause serotonin syndrome when used with antidepressants (5.2) May cause falling asleep during activities of daily living, daytime drowsiness, and somnolence (5.3) May cause hypotension, especially orthostatic (5.6) May cause or exacerbate dyskinesia. Decreasing the levodopa dose may lessen or eliminate this side effect (5.7) May cause hallucinations and psychotic-like behavior (5.8) May cause impulse control/compulsive behaviors (5.9) May cause withdrawal-emergent hyperpyrexia and confusion (5.10) ADVERSE REACTIONS Most common adverse reactions (incidence 3% or greater than placebo): Rasagiline monotherapy: flu syndrome, arthralgia, depression, dyspep Citiți documentul complet